Prostate Cancer | Specialty

Robust Sipuleucel-T Immune Activity Is Detailed in Pooled Data Analysis

October 24th 2012

Patients who received sipuleucel-T developed immune parameters that correlated with improved overall survival suggesting that these parameters should be the focus of further studies on the treatment.

Blood Test Monitors Response to Treatment in Metastatic Prostate Cancer

October 23rd 2012

A novel assay could determine when patients with metastatic prostate cancer begin to relapse on androgen deprivation therapy, and which patients may respond better to second-line therapies.

Urology Practices Organize to Deliver Comprehensive Cancer Care: An Interview With Daniel R. Saltzstein, MD

October 22nd 2012

Daniel R. Saltzstein, MD, describes steps Urology San Antonio has taken toward creation of a comprehensive urologic care practice, including establishment of a bone health clinic and an advanced prostate cancer clinic.

Dr. James Mohler Discusses Androgen-Deprivation Therapy

October 16th 2012

James Mohler, MD, from Roswell Park Cancer Institute, discusses androgen-deprivation therapy, a standard treatment for men with metastatic prostate cancer.

Dr. Petrylak on Enzalutamide's Role in Prostate Cancer

October 9th 2012

Daniel P. Petrylak, MD, from the Smilow Cancer Center, discusses the recent approval and future role of enzalutamide for patients with prostate cancer.

Urology Practices Form Collaborative Partnerships With Specialty Pharmacy Providers

October 9th 2012

Novel formulations of specialty drugs have shifted the treatment of patients taking oncologic and biologic agents from infusion centers to the doctor's office.

Immunotherapy: Personalized Treatment for Advanced Prostate Cancer

September 19th 2012

In April 2010, the FDA approved sipuleucel-T for patients with castration-resistant and metastatic prostate cancer, providing a new treatment that would help the body fight its own cancer.

Final Results of Abiraterone Acetate in Advanced Prostate Cancer Show Significantly Improved Survival

September 18th 2012

Abiraterone acetate significantly improved overall survival with positive responses seen in several subgroups of patients with metastatic castration-resistant prostate cancer.

Clinical Insights Into Genitourinary Cancer

September 12th 2012

A quick glance at a recent study examining the renal cell carcinoma immunotherapy AGS-003 and the FDA approval of a new noninvasive prostate health index test.

Dr. Petrylak Explains How Sipuleucel-T Impacts Survival

September 7th 2012

Dr. Daniel Petrylak, from the Smilow Cancer Center at Yale-New Haven, Explains the Correlation Between Immune Response to Sipuleucel-T and Survival.

“Male Lumpectomy” Emerges as New Option in Prostate Cancer: An Interview With E. David Crawford, MD

September 6th 2012

Targeted focal therapy offers some men with localized prostate cancer a solution between active surveillance and definitive treatment with surgery and/or radiation.

Enzalutamide Approved for Late-Stage Prostate Cancer

August 31st 2012

The FDA approved enzalutamide for use in patients with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel and hormonal therapy.

Dr. Mohler Discusses Prostate Cancer Trial Endpoints

August 30th 2012

Dr. James Mohler, from Roswell Park Cancer Institute, Discusses the Need for Intermediate Endpoints for Early Stage Prostate Cancer Trials.

FDA Grants Priority Review to New Indication for Abiraterone Acetate

August 29th 2012

The FDA announced that Priority Review has been granted to abiraterone acetate for certain advanced prostate cancer cases based on positive data presented at the ASCO annual meeting.

Identification and Prevention of Skeletal-Related Events

August 27th 2012

Immunotherapy for Castration-Resistant Prostate Cancer

August 27th 2012

Optimal Treatment Sequencing for Advanced Prostate Cancer

August 27th 2012

Therapeutic Options for Advanced Prostate Cancer

August 27th 2012

Evidence-Based Care for Localized Prostate Cancer

August 27th 2012

Deciding Treatment Options for Early-Stage Prostate Cancer

August 27th 2012